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Amylin appcurs to interI& with the action of insulin in muscle and possibly in liver. WC have altcmptcd to delcct a direct antagonism belwccn 
amylin and insulin in culrured riil hqxtocytcs, The stimulation of glurokinasc gene expression was used as a marker of insulin aaion. Amglin proved 
incffccGvc in suppressing subsequent uccumulaGon of ylucokinasc mHNA in response 10 maximal or submaximal doses of insulin. When applied 
to cells already induced by prior incubation with insulin done. amylin failed IO reverse induclion. in contrast to the cl%cGvcness ofglucagon under 
the sunu conditions. Thus . ::?::‘I;!I is no1 a physiological anttiyonist ot’ insulin in the control of hcpatic glucokinasc gcnc expression, 
Amylin: Insulin: Glucokinasc; Gene expression; Hcpa~ocyu; Liver 
1. INTRODUCTION 
Amylin, also referred to as islet amyloid polypeptide, 
is the major protein component of the hy;lline deposits 
found in the islets of Langerhans of a majority of pa- 
tients with non-insulin-dependent diabetes mellitus 
[1,2]. This polypeptide is synthesized in precursor form 
in the @ cells of the islets. Mature amylin. which is 37 
amino acids in length and amidated at its carboxy-ter- 
minal end, is secreted from the cells and can either 
accumulate locally as amyloid fibrils or enter the vascu- 
lar system and circulate in plasma (for review, set [3]). 
Circulating amylin is thought to act as a hormone on 
target tissues. Because of effects that are opposed to 
those of insulin, amylin may be a contributing factor of 
the insulin resistance associated with non-insulin-de- 
pendent diabetes [4]. 
The major target of amylin action appears to be skel- 
etal muscle. In the isolated rat soleus muscle prepara- 
tion, amylin was shown to reduce basal and insulin- 
stimulated incorporation of glucose into glycogcn [5,6]. 
This effect has recently been traced to a stimulation of 
phosphorylase a activity, which can be overcome by 
insulin at submaximal doses of amylin [73. Consistent 
with this in vitro effect, the infusion of amylin during 
a hyperinsulincnlic glucose clamp in rats and dogs re- 
sulted in a decrease in peripheral glucose utilisation 
[8,9]. In glucose clamp experiments, amylin was also 
reported to antagonize the insulin suppression of he- 
patic glucose production, suggesting that the liver might 
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be an additional target issue for amylin [S-lo]. Concen- 
trations of amylin that are several orders of magnitude 
higher than measured plasma levels appear to be rc- 
quircd to elicit anti-insulin effects, both in intact ani- 
mals and in isolated tissue preparations [I I]. The relc- 
Vance of these effects to glucose homeostasis n normal 
or disease states remains therefore uncertain. 
The present work was undertaken in an attempt to 
demonstrate a direct anti-insulin effect of amylin at the 
level of the liver cell. The insulin response under study 
was the induction of mRNA coding for the regulatory 
enzyme of glucose metabolism gIucokinase (P,TP: D- 
hexose 6-phosphotransferase, EC 2.7. I. 1). We [ 121 and 
others [13] have shown that acute administration of 
insulin to streptozotocin-diabetic rats results in a rapid 
stimulation of glucokinase gene transcription in the 
liver, leading to a massive accumulation of hepatic glu- 
cokinase mRNA. More recently, the same erect of insu- 
lin was elicited in rat hepatocytes maintained in primary 
culture [14,15]. In addition, glucagon and derivatives of 
CAMP were shown to inhibit the insulin effect in cul- 
tured hepatocytes [14]. The glucokinase gene response 
in cultured hepatocytes i both rapid and of large mag- 
nitude, making this system attractive for studying the 
mechanism of insulin action and for ideniifying effec- 
tors with insulin-like or anti-insulin activities. In the 
Fresent paper, we make use of this system to address the 
issue of a direct antagonism between insulin and amylin 
at the hepatic level. 
2. MATERIALS AND METHODS 
Heptizocytcs were isolaled from 48-h fasted malt Wistar rills (ap- 
proximotcly 220 g in hody wcighl) by collaynast perfusion of the liver 
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and cuhurcd :IS dcscribud previously [Id]. Cells wcrc sccdcd in 55 cm’ 
pluslic dishes at ;I ccl1 density of 3.SxlO” cells per dish and cuhurcd 
in RPM1 I640 nxdium with ihe I’ollowing additions, Fetal bovine 
strum was prcsel;t at :I concentrution of IO% (v/v) Ibr a 3-h attachmrm 
period ;III~ at 5% for the rcmnindcr ol’ the experiments. Dexam- 
cllli;~soix (IO-’ M). penicillin (I IO U/nil) nnd streptomycin (I 10 j4) 
wcrc prcscnt throughout, III ~111 cspcriinents, IIIC cells wcrc fed fresh 
medium 20-25 h ;Ilicr seeding ilnd amylin or insulin wcrc‘ itddcd 2 h 
IillCl’. 
R;I~ ;nnylin wns u gcncrous gift of Dr. Timothy J. Rink of the 
Amylin Corporation (SW Diego. CA). Two diainci batches ofamylin 
wcrc used in the prcscot rxpcrimcnts with identical results. Both 
butches wcrc tcslcd for biological xliviry ill lhc Amylin Corporation 
ilnd sho~.n to inhibit the insulin-s~i~~~ul;lt~d incorporution of rudiouc- 
~ivc glucose into glysogcn in the r;ll solcus muscle syslcm [a]. Highly 
purilicd humun insulin (Actrnpid H bl I’roni Novo. Copcnhugen. Dcn- 
mark) wus used, Highly puriticd porcine ylucugon was ;I kind gift of 
Dr. List G. Haling of the Nova Rcsr;lrch Institute. 
Al the’ tjmcs sclcc~tl Ibr RNA isoliliion. the hcp:~~ocyics wcrc rap- 
idly w;~shcJ 2 tinxs whh 4-S ml of ice-cold phosphate-buffered sulinr 
and scraped into 2 ml ol’guanidinium Wocyaxuc solution. This solu- 
lion as well as thy’ subscqucnt cxtrxtion willi phenol-chlorolbrnm tit 
acid pi-l wcrc iIs dcscribcd by Chomczynski und Succhi [ 161. Following 
isoprop;lnol precipitation. the RNA p~llcts were rc-dissolved in the 
guanidinium lhiocyan:itc solulion and prccipitilted ;Ipilin with iso- 
proprmol. Thcsc sops wcrc rcpC:ncd once more and thc finul RNA was 
dissolved in \\‘iIW. prccipilillcd willi CtllilllOl in prcscncc 0T SodiUllI 
:ICC~;IN und tinally dissolvsd in waic’r. Samples 01. IB pug RNA wcrc 
dcnaiurcd with glyos;~l and dimcihylsulfoxidc at OX, rcsolvcd by 
clcciraphorcsis in I% (w/v) ugurosc gels and transferred clcciro- 
phorulisally to unshargcd Nylon Mcnibranes (GcncScrccn from N EN 
Rcscurch P~OLI~ICIS. Boslon. MA). Pr4iybridizution, hybridizetion 
und w;ishing or the mcmbr;lncs wcrc pcrl’ormed ;IS described [I?], The 
probe wils the 2.45 kbp glucokinusc GK? cDNA [ 171, Wlnbulcd by 
riildm priming. 
3. RESULTS 
The first aim of this study was to find out whether the 
addition of amylin to primary cultures of rat hepato- 
cytes would compromise subsequent induction of glu- 
cokinasc mRNA by insulin. Cells were challenged with 
increasing doses of amylin 30 min before addition of a 
fixed dose of insulin. The dose of insulin (2.6~10-~ M) 
and the time ofexposure of the cells to insulin (8 h) were 
chosen. on the basis of previous work [14] to ensure 
maximal accumulation of glucokinase mRNA. As may 
be seen in Fig. I, the inductive ffect of insulin was fully 
preserved at all amylin concentrations tested, The range 
of concentrations extended from 10-l’ to lo-’ M. For 
comparison, it should be noted that the ECSo for the 
effect of amylin in the isolated soleus muscle was 7x10-” 
M (T.J. Rink, personal communication), 
The above data demonstrate that the maximal effect 
of insulin on glucokinase gent expression is not dimin- 
ished by amylin, even at pharmacological concentra- 
tions. We next wanted to determine whether the sensi- 
tivity of cultured hepatocytes to insulin, i,e. their re- 
sponse to low insulin doses. would be altered in pres- 
ence of amylin. To this end, &a-respcnse experiments 
in which the insulin concentration was varied and the 
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Fig. I. Effect of a maximal dose of insulin on glucokinase mRNA in 
prcscnce of various concentrations or umylin. The induction of glu- 
cokinasc mRNA was sUied in cullurcd rai hepatocytcs. Northern 
blot unulysis was pcrrornxd with totill cellular RNA. An autorudi- 
ogixm 01’ the blot hybridized with ;I glucokin::sc cDNA probe is 
shown. 
amylin concentration was kept constant, were per- 
formed. The Northern blot in Fig. 2 (panel A) illustates 
the response of cells incubated with increasing doses of 
insulin, alone or in the presence of IO-” M amylin. As 
may be seen, the insulin-dependent accumulation of glu- 
cokinase mRNA was similar in absence or presence of 
amylin. Additional experiments of the same design in 
which amytin was supplied to cells at a concentration 
of IO-’ M, are summarized in Fig. 2 (panel B). The 
dose-response curves for the insulin effect on glucoki- 
nase mRNA were found to be completely superimposa- 
ble in absence or presence of amylin. Thus, the sensitiv- 
ity of liver cells to insulin is not impaired in presence of 
amylin. 
In the experiments described so far, cells were pre- 
sented virtually simultaneously with amylin and insulin. 
We next attempted to determine whether amylin would 
de-induce glucokinase mRNA in cells cultured initially 
with insulin alone. In the experiment of Fig. 3, hepato- 
cytes were cultured for 13 h in medium containing 
2.6~10-~ M insulin, to maximally induce glucokinase 
mRNA. At the end of this period (time 0 in Fig. 3), 
amylin was added and culture was continued for the 
specified time intervals before cell harvest and RNA 
isolation. For comparative purpose, companion cells 
were challenged with glucagon instead of amylin. As 
expected from previous work [14] glucagon caused a 
rapid drop of glucokinase mRNA such that 20% of the 
initial level was left after 120 min and less than 4% after 
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Fig. 2. Dose-rcsponsc cfkct of insu!in on glucokiml~ mRNA in prcsc~~c or abscncc oTamylin. Panel A: nutoradiogram of a Nor%& blot. Where 
indicalud. umylin W;IS prcscnt ai 1 lixcd ~OIICLYI~~~OI~ ol’ I &IIIU;M. Lunc I. hcpatocytcs cultured without insulin; lanes 2-6. hcpatocytes cultured 
with 0.3, 0.1. 0.8. I.6 and 25.6 nM insulin. rcspcclivcly. Daub with or wilhou umylin wcrc obtained wjith the same batch of hcpatocytes. Panel D: 
quuntilicution 01’ the d;ILI I’roni 3 scpuratc sspcrimcnts b;, laser dcnsilomctcr scimniny al’;mtoradiogranis. Where indicalcd. amylin was present 
11 ;I conccntrxtion ol’ 100 nM. The IIICUIIS and rang ol’ vnlucs arc given. 
230 min. In contrust, the level of mRNA remained un- 
changed following amylin addition. The amount of mes- 
sage was also stable in cells cultured with insulin and 
receiving no further addition (not shown). 
4. DISCUSSION 
Amylin does not antagonize the effect of insulin on 
glucokinase gene expression in the liver cell. As shown 
previously [141 and further documented here, insulin 
induces a rapid and massive build-up of glucokinasc 
tnRNA in rat hepittocytes maintained in primary cul- 
ture. Neither the amplitude of the inductive response to 
supramaximal doses of insulin, nor the cell sensitivity 
to low doses of insulin, were diminished when amylin 
was added to the culture medium shortly before insulin. 
Furthemorc, amylin was unable to effect a reduction 
in the level of the message, when the latter was first 
raised by culture of the hepatocytcs with insulin alone. 
The ineffectiveness of amylin is in distinct contrast o 
the negative control exerted on the glucokinasc gene by 
glucagon and cAMP. We showed in previous work, 
using a protocol similar to that of Fig. 1. that the insu- 
lin-induced accumulation of glucokinase tnRNA is pro- 
gressively inhibited by increasing doses of glucttgon, an 
effect mimicked by 8-chlorophcnylthio-CAMP [14]. In 
addition. as shown in Fig. 3, glucagon rapidly reverses 
full-blown induction brought on by prior exposure to 
insulin. The rapid de-induction by glucagon shown here 
agrees with our earlier kinetic study performed with 
E-chlorophenylthio-CAMP [14]. From the contrasting 
data obtained with glucagon/cAMP on the one hand 
and amylin on the other, we infer that atnylin does not 
effectively trigger a CAMP signal in the hepatocyte. This 
conclusion does not support an earlier suggestion of 
umylin acting via binding to an adenylate cyclase-cou- 
pled receptor, the calcitonin gene-related polypeptide 
receptor, in the plasma membrane of the hepatocyte 
[181. 
During the preparation of this manuscript, Gomez- 
Foix et al, [I91 reported that amylin counteracts the 
stimulatory effect of insulin on glycogen synthesis in 
freshly isolated rat hepatocytes. Their data may suggest 
that amylin cot!ld interfere with a branch of the insulin 
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Fig. 3. Revcrsa .I of insulin induction by glucagon but not by amylin. 
Cultured hcput~cyzcs wcrc induced with insulin for 13 h prior to 
addition or umylin (I &mu:M) or glucapon (I nML7imc C is the time 
ol’ thcsc additions. Tk cffccts of amylin and glucagon wcrc studied 
in the same batch of hcpntocytes. An autoradiogram of Northern blot 
is shown, 
I17 
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signal transduction pathway involved in the regulation 
of hepatic glycogen mctabohsm, but not in the control 
of glucokinase gene expression. They are difficult to 
reconcile, however, with recent metabolic studies using 
the isolated perfused liver, which failed to reveal an 
anti-insulin action of amy!in [20]. Furthermore, while 
our work was in progress, Stephens et al. [21] have 
reported their inability to detect specific binding sites 
for amylin in the plasma membrane of rat hepatocytes. 
The lack of receptor for amylin in the liver cell would 
a fortiori preclude specific effects of the peptide in this 
cell type. The data presented here are consistent with 
such a notion. 
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